Lifetime cost effectiveness of simvastatin in a range of risk groups and age groups derived from a randomised trial of 20,536 people.
OBJECTIVES: To evaluate the cost effectiveness of 40 mg simvastatin daily continued for life in people of different ages with differing risks of vascular disease. DESIGN: A model developed from a randomised trial was used to estimate lifetime risks of vascular events and costs of treatment and hosp...
| Auteurs principaux: | , , , , , |
|---|---|
| Format: | Journal article |
| Langue: | English |
| Publié: |
2006
|